Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study

The Real-WECAN study evaluated the real-life effectiveness and safety of canagliflozin 100 mg daily (initiated in SGLT-2 inhibitors naïve patients) and canagliflozin 300 mg daily (switching from canagliflozin 100 mg or other SGLT-2 inhibitors) in individuals with type 2 diabetes. The objectives of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorgojo-Martinez, Juan J., Brito-Sanfiel, Miguel, Antón-Bravo, Teresa, Galdón Sanz-Pastor, Alba, Wong-Cruz, Jaime, Gargallo Fernández, Manuel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573752/
https://www.ncbi.nlm.nih.gov/pubmed/36233490
http://dx.doi.org/10.3390/jcm11195622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573752/
https://www.ncbi.nlm.nih.gov/pubmed/36233490
http://dx.doi.org/10.3390/jcm11195622

Ejemplares similares